HCV Triple Regimen
Drug therapy for the more than 150 million patients worldwide with chronic HCV infection is evolving toward combination regimens that, ideally, produce sustained virologic response (SVR) across genotypes, are well-tolerated, and taken once-daily for a short duration of therapy (less than 12 weeks). This ideal regimen will likely include a combination of direct-acting antiviral agents inhibiting NS5A, NS3, and NS5B nucleoside polymerase.
The worldwide license and collaboration agreement between Achillion and Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, was established to develop and commercialize such a regimen. Janssen is aggressively pursuing a potentially best-in-class, short-duration combination oral regimens for HCV with odalasvir, Achillion’s second generation NS5A inhibitor, and its own agents simeprevir and ALS-335.